This article is the last in a series of 3 examining the methodological issues in measuring rates of TIA and strokeassociated dementia. The 2 previous articles have shown that widely used baseline selection criteria and selective attrition from face-to-face follow-up result in TIA and stroke cohorts that are unrepresentative of the whole with those at highest risk of dementia being excluded. 10, 11 This third article examines the third and final major potential source of bias in assessing cognitive outcomes after TIA and stroke: the applicability of cognitive tests. Previous studies in noncerebrovascular populations have shown that sensory impairments and more severe cognitive impairment impact on the applicability of such tests [12] [13] [14] and that cognitive impairment associates with frailty. 15 We therefore hypothesized that risk factors for dementia including nonstroke characteristics such as older age and sensory deficits as well as more severe cerebrovascular events, would be associated with untestability in TIA and stroke but there are few data from inclusive cohorts with long-term follow-up. Background and Purpose-Cognitive assessment is recommended after stroke but there are few data on the applicability of short cognitive tests to the full spectrum of patients. We therefore determined the rates, causes, and associates of untestability in a population-based study of all transient ischemic attack (TIA) and stroke. Methods-Patients with TIA or stroke prospectively recruited (2002)(2003)(2004)(2005)(2006)(2007) 
C
ognitive screening is recommended after stroke to guide clinical management and to measure outcome in stroke trials because stroke increases the risk of dementia, and dementia predisposes to stroke. [1] [2] [3] Short cognitive tests are required because long batteries of tests are not practicable outside small-scale research studies. 4 Existing studies on short cognitive tests such as the mini-mental state examination (MMSE) 5 and Montreal Cognitive Assessment (MoCA) 6 have demonstrated their validity against neuropsychological batteries in selected subgroups 4, 7, 8 but the applicability of these tests to the total population (ie, the proportion testable) with transient ischemic attack (TIA) and stroke is unclear.
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We therefore undertook a longitudinal population-based study of all TIA and stroke to determine the rates, reasons, and associates of untestability using a short cognitive test (MMSE, 5 MoCA, 6 telephone interview for cognitive status, 16 and abbreviated mental test score 17 ) with follow-up to 5 years.
Methods
Patients with TIA or stroke were prospectively recruited from 1 April, 2002 to 31 March, 2007 into the Oxford Vascular (OXVASC) Study, a prospective population-based cohort study of all acute vascular events occurring within a defined population of 92 728 covered by 100 general practitioners (primary care) in 9 general practitioners practices in Oxfordshire, United Kingdom. 18, 19 The study was approved by the local research ethics committee. Informed written consent (or assent from relatives) was obtained for study interview and follow-up either in person or where not possible, by telephone, and also consent/assent for indirect follow-up using primary care physician records, hospital records, and death certificate data. In cases where patients died before first assessment or where a family member could not be contacted for assent in patients lacking capacity (eg, owing to dysphasia or dementia), the ethics committee approved review of the patient's medical records.
The methods of OXAVSC have been described in detail elsewhere. 18, 19 Patients were ascertained as soon as possible after the initial TIA or stroke by study clinicians through a combination of hot and cold pursuit. 20 TIA and stroke were defined clinically by World Health Organization criteria. 21 Stroke was dichotomized as minor or major using a cut-off of >3 on the National Institutes of Health Stroke Scale (NIHSS) as this had been previously found to discriminate best between those seen in the emergency clinic versus those presenting directly to the emergency department. 22 Baseline brain and vascular imaging was performed and all cases were reviewed by a senior vascular neurologist (P.M.R.). Leukoaraiosis was defined as absent, mild, moderate, or severe as described previously. 23 Patient data were collected by interview using a standardized form and general practitioner records. 18, 19 Risk factors were recorded at study entry. Functional status, assessed using modified Rankin 24 and Barthel 25 scores, was done at baseline and at all follow-ups. Follow-up interviews were done by trained research nurses at 1 and 6 months and 1, 5, and 10 years either in the outpatient clinic or by home visit where hospital clinic visit was not possible. Telephone or e-mail follow-up was performed where face-to-face follow-up was not possible.
Cognitive testing was done at all follow-ups as described previously 10,11 using at least 1 of the MMSE, 5 MoCA, 6 and telephone interview of cognitive status, 16 27 was done by telephone when face-to-face followup was not feasible. Reasons for cognitive untestability and problems with cognitive testing in otherwise testable patients including visual impairment, hemiparesis, and dysphasia were recorded. 28 The methods of dementia ascertainment have been described elsewhere.
10,11
Statistical Analysis
Surviving patients were classified as assessed if they had any type of study assessment versus not assessed if they did not. Within the assessed group, patients were classified as testable if a cognitive test could be undertaken versus untestable if it could not. Within the testable group, patients were classified as fully testable if there was no problem interfering with testing versus testable but with a problem if there was a problem, such as poor vision that interfered with testing. Reasons for lack of study assessment were examined in the 2 previous articles on baseline selection bias, and attrition on followup of patients included in the study at baseline. 10, 11 For this article, we examined the testability (with a short cognitive test) of the group of patients who had received a study assessment at each given time point. The characteristics of the testable and untestable patients were compared within the group of assessed patients and nonassessed survivors were not included in the untestable group because testing was never attempted in these patients. Demographic and clinical differences between dead and surviving, tested and untestable patients and those completing a test versus those with problems with testing were compared using ANOVA or χ 2 test as appropriate. Hazard ratios (HRs) for death before next follow-up were calculated for untested versus testable patients adjusted for age and event severity.
Results
One thousand two hundred thirty-six patients were ascertained (mean: age/SD 75. Rates of study assessment, cognitive testability, and problems with testing in otherwise testable patients at baseline and for each follow-up point to 5 years are shown in Figure 1 . The median (interquartile range) time from event to baseline assessment was 4 (2-8) days. Among assessed survivors, numbers testable with a short cognitive test were 835/1097 (76%) at ascertainment, 778/947 (82%) at 1 month, 756/857 (88%) at 6 months, 692/792 (87%) at 1 year, and 472/567 (83%) at 5 years (Figures 1-3 ; Tables I-V in the online-only Data Supplement). Eighty-eight percent (331/378) of assessed patients with TIA were testable at baseline compared with only 46% (133/290) of assessed major stroke survivors ( Figure 3 ). The proportion of untestable major stroke survivors fell with time after event, whereas the proportion of untestable TIA survivors did not ( Figure 3 ). Testable patients were younger, and had less premorbid disability and less pre-and postevent dementia, even after adjustment for age, than untestable patients (all P<0.001; Tables I-V in the onlineonly Data Supplement).
Untestability at baseline was associated with greater risk of death on follow-up even after adjustment for age and severity of index event (adjusted HR for death before 5 years was 1 (Figures 1-3 ; Table) . Testable patients with problems interfering with testing were older, had more severe events, more premorbid dependency and more dementia than those without testing problems (Tables I-V in Table) .
Discussion
In our longitudinal study of short cognitive tests in >1000 patients with TIA and stroke from a defined population, a quarter of all assessed patients were untestable at baseline including nearly a half of those with major stroke. Around a sixth of those tested at baseline had a problem interfering with testing usually from stroke-related impairments, such as dysphasia. On follow-up, rates of untestability were generally lower. As well as severity of event, untestability was associated with older age, premorbid dependency, and both pre-and postevent dementia.
We designed our study using short cognitive tests rather than a neuropsychiatric battery to facilitate obtaining cognitive data on as many patients as possible in a large pragmatic study, which included multiple noncognitive assessments. Our findings demonstrate that requiring completion of even a short cognitive test as a condition of entry into a study or to measure cognitive outcome will result in a selected unrepresentative subgroup of patients. This effect will probably be greater in studies using extensive neuropsychological batteries, which are poorly tolerated by frail elderly patients although there are few reported data. Untestability and problems with testing in testable patients were associated with risk factors for poststroke dementia and it was thus unsurprising that rates of both pre-and postevent dementia were significantly higher in these groups. Requiring completion of a cognitive test will, therefore, result in underestimation of the true cognitive impairment rate. 29 The problem of missing cognitive data resulting from untestability will be greatest in studies of severe (hospitalized) stroke and least in studies of TIA. The vast majority of patients with TIA and most patients with minor stroke were testable at baseline and rates of untestability only rose at 5 years when patients moved out of study area and telephone assessment was not feasible. The proportion of testable survivors increased with time since event probably because of a combination of high death rates in untestable patients and some recovery in survivors, particularly in those with major stroke. 11, 30 Two recent studies of hospitalized patients with stroke have shown slightly higher baseline testability rates by guest on April 15, 2017 http://stroke.ahajournals.org/ Downloaded from using the MoCA although the cohorts were overall younger than in this study. 31, 32 Concerning the specific reasons for untestability, acute stroke effects including in order of prevalence, dysphasia, reduced conscious level, hemiparesis, and delirium were common in the acute phase with findings similar to those of the Heidelberg study. 32 Residual effects of stroke prevented testing less commonly at later time points when sensory difficulties (eg, deafness) and moving away became more important. Rates of dementia severe enough to preclude testing remained relatively constant. Similarly, problems interfering with testing were related to acute stroke effects soon after the event, whereas unrelated problems such as poor vision were more important at later follow-ups. Sensory deficits or other nonstroke-related problems such as dominant arm disability, fatigue, and frailty will be an issue for any study assessing cognition (and indeed will have meant that some patients would have been untestable even before their cerebrovascular event) but such data are rarely included in published studies, 4, 9 despite the fact that such testing difficulties may lead to inappropriate classification of cognitive impairment or exclusion of those at-risk. [12] [13] [14] [15] Strengths of our study include the ascertainment and follow-up to 5 years and beyond of all TIA and stroke from a defined population and the careful prospective documentation of reasons for untestability and problems with testing. Our data further the understanding of the applicability of short cognitive tests to the population with TIA and stroke, many of whom are elderly with significant comorbidity. There are however, some limitations to our study. First, we did not formally compare the feasibility of the different short tests but few patients completed the MMSE and not the MoCA at 5 years when both tests were (29) 28 (17) 14 (14) 13 (13) 7 (7) Unwell/reduced conscious level 58 (22) 16 (9) 7 (7) 7 (7) 2 (2) Moved away and no telephone test N/A 8 (5) 27 (27) 30 (30) 33 (33) Visual impairment/deafness 8 (3) 2 (1) 0 (0) 1 (1) 1 (1)
Dementia 11 (4) 10 (6) 10 (10) 6 (6) 6 (6) Acute confusion/delirium 11 (4)
Late ascertainment/referral 40 (15) 54 (32) 13 (13) 1 (1) 0 (0) Recurrent event 1 (<1) 3 (2) 14 (14) 19 (19) 28 (28) Other/no reason recorded 41 (16) 32 (19) 9 (9) 4 (4) (20) 16 (22) 9 (14) 4 (7) 5 (8) Dysphasia 7 (10) 13 (18) 15 (24) 17 (29) 7 (11) Acute confusion/delirium 15 ( administered (ie, patients completed both or neither) and where only 1 test was done, this was usually because of fatigue or patient/carer distress. Second, reasons for untestability included lack of patient availability to do a cognitive test in those who were assessed, because the patient had moved away and was unable to do a telephone test or because information was received via an informant but this is likely to be an issue for all longitudinal studies with long-term follow-up. Third, researchers did not always record the reason for lack of cognitive test and in some cases this may have been for logistical reasons such as lack of time rather than patient factors.
In conclusion, untestability with a short cognitive test after TIA and stroke was associated with risk factors for poststroke dementia including older age and more severe stroke and nearly a half of those assessed with major stroke were untestable at baseline. Large studies or trials relying on cognitive test results alone to inform cognitive impairment should report data on untestable patients, correct for problems interfering with testing, and include risk factor adjusted estimation of probability of impairment in nontested patients.
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